ArticleCurrent microbiology2025
Isolation and Characterization of A Novel Pbunavirus with Promising Antibiofilm Activity Against Pseudomonas Aeruginosa.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Protecting Newborns from Multidrug-Resistant Infections: The Emerging Role of Bacteriophages.Viruses · 2026Review
- A temperate phage encoding a catalytically active endolysin: characterization of phage P7869 and its Lys7869 against Pseudomonas aeruginosa.BMC microbiology · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Characterisation of a NovelPathogens (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Endolysin, encoded by bacteriophages, has emerged as a promising candidate against antibiotic-resistant bacteria due to its ability to target bacterial cell walls. In this study, we isolated a new bacteriophage vB_PaeC_sem1 from sewage. The genome of vB_PaeC_sem1 is 66,420 bp, a double-stranded linear DNA that comprises 92 open reading frames (ORFs). Sem1 showed broad stability across various temperatures, pH, and chemical solutions. Heterologous expression of Lys N in Escherichia coli was done (LysN1). The antibacterial effects of Lys N1 were shown against Pseudomonas aeruginosa and its biofilm disruption. Recombinant LysN1 and LysN effectively lysed P. aeruginosa as well as, destroying up to 80% and 67% of bacterial biofilm (respectively). No toxic effects on A549 cells were detected. These results suggest Sem1 as a potential alternative for treating Gram-negative bacterial infections.
Indexed as
Identifiers
40960506What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.